Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Tax-Provision" stands at 4.09 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Eli Lilly and Company's third quarter result of 1.65 Billion USD for the item "Tax Provision" represents an increase of 47.85 percent compared to it's second quarter result.
Also, Eli Lilly and Company's third quarter result of 1.65 Billion USD for the item "Tax Provision" represents an increase of 166.93 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 4.09 Billion USD for the item "Tax Provision" represents an increase of 33.72 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 129.78 percent compared to the value the year prior.
The 1 year change in percent is 129.78.
The 3 year change in percent is 691.85.
The 5 year change in percent is 380.62.
The 10 year change in percent is 717.48.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Johnson & Johnson - Tax Provision | 486,508,953,600.00 |
![]() | AbbVie Inc - Tax Provision | 399,570,305,024.00 |
![]() | Roche Holding AG - Tax Provision | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Tax Provision | 280,205,508,085.11 |
![]() | Novartis AG - Tax Provision | 255,096,620,580.91 |